iBio Inc. (AMEX:IBIO) traded with a subtraction of -$0.04 to $0.31 on Thursday, a downside of -10.35 percent. An average of 781,373 shares of common stock have been traded in the last five days. There was a fall of -$0.1210 in the past week, and it reached a new high 3 times over the past 12 months. The last 20 days have seen an average of 915,203 shares traded, while the 50-day average volume stands at 625,873.
IBIO stock has decreased by -40.37% in the last month. The company shares reached their 1-month lowest point of $0.3000 on 08/24/23. With the stock rallying to its 52-week high on 03/21/23, shares of the company touched a low of $0.34 and a high of $16.51 in 52 weeks. It has reached a new high 12 times so far this year and lost -30.22% or -$0.1344 in price. In spite of this, the price is down -98.12% from the 52-week high.
Top 5 AI Stocks to Buy for 2023
The artificial intelligence (AI) revolution is already here. And it's about to change everything we know about everything.
According to Grand View Research, the global AI boom could grow from about $137 billion in 2022 to more than $1.81 trillion by 2030. And investors like you always want to get in on the hottest stocks of tomorrow. Here are five of the best ways to profit from the AI boom.
Click Here to Download the FREE Report.
Sponsored
Insider Transactions
IBIO stock investors should be aware that iBio Inc. (IBIO) stock had its last reported insider trading activity 28 days ago on Jul 27. In this transaction, the insider spent $2,308. Brenner Martin, disposed of 47,020 shares at a price of $0.59 on Jul 12. The insider now owns more than $27,521 worth of shares. Prior to that, Brenner Martin went on to Sale 4,184 shares at $0.68 each on Jun 21. An amount of $2,849 was transacted.
Valuation Metrics
iBio Inc. (IBIOstock’s beta is -3.12. Other valuation ratios to consider include the trailing price-to-sales (P/S) ratio at 15.07, the price-to-book (PB) ratio at 0.23.
Financial Health
Further, the company has a long term debt to equity ratio of 0.04 and a total debt to equity ratio of 0.85 for the quarter ending September 29. iBio Inc.’s EBITDA margin for the year ending September 29 is -1951.24%. Its gross profit as reported stood at $2.17 million compared to revenue of $2.38 million.
For investors, determining the potential profitability of the investment also depends on the performance of the company’s management. In the past 12 months, iBio Inc.’s return on assets was -108.60%.
Earnings Surprise
The company posted a net income of -$7.29 million in the quarter, while revenues of -$33.55 million were shrunk -63.79%. The analyst consensus anticipated iBio Inc.’s latest quarter earnings to come in at -$1.85 per share, but it turned out to be -$2.05, a -10.80% surprise. For the quarter, EBITDA amounted to -$5.84 million. Shareholders own equity worth $16.8 million.
Technical Picture
From a technical analysis perspective, let’s take a brief look at iBio Inc. (IBIO) price momentum. RSI 9-day as of the close on 23 August was 22.26%, suggesting the stock is oversold, with historical volatility in this time frame at 64.41%.
As of today, IBIO’s price is $0.3581 -28.07% or -$0.1210 from its 5-day moving average. IBIO is currently trading -38.61% lower than its 20-day SMA and -85.10% lower than its 100-day SMA. However, the stock’s current price level is -58.75% below the SMA50 and -82.58% below the SMA200.
The stochastic %K and %D were 2.59% and 2.58%, respectively, and the average true range (ATR) was 0.0529. With the 14-day stochastic at 2.78% and the average true range at 0.0530, the RSI (14) stands at 26.70%. The stock has reached -0.0515 on the 9-day MACD Oscillator while the 14-day reading was at -0.0875.
Analyst Ratings
JMP Securities launched coverage on iBio Inc. (AMEX: IBIO) in its analyst report released on November 29, 2021. The firm assigned the stock a Mkt outperform rating. The consensus rating for iBio Inc. (IBIO) among analysts is Hold. According to current brokerage recommendations, 0 brokerage firms advise that investors sell IBIO, while 1 suggest investors hold. There are 0 analysts who rate the stock as underweight. The stock is rated overweight by 0 analysts, while 0 others rate it as a “buy”.
What is IBIO’s price target for the next 12 months?
Analysts predict a range of price targets between $1.00 and $1.00, with a median target of $1.00. Taking a look at these predictions, the average price target given by analysts for iBio Inc. (IBIO) stock is $1.00.
